KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) FCF Margin (2016 - 2025)

Historic FCF Margin for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to 12.79%.

  • Alnylam Pharmaceuticals' FCF Margin rose 302800.0% to 12.79% in Q4 2025 from the same period last year, while for Dec 2025 it was 14.78%, marking a year-over-year increase of 166700.0%. This contributed to the annual value of 12.53% for FY2025, which is 144300.0% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its FCF Margin stood at 12.79% for Q4 2025, which was up 302800.0% from 25.06% recorded in Q3 2025.
  • Alnylam Pharmaceuticals' FCF Margin's 5-year high stood at 45.61% during Q3 2023, with a 5-year trough of 424.28% in Q1 2025.
  • In the last 5 years, Alnylam Pharmaceuticals' FCF Margin had a median value of 34.67% in 2022 and averaged 51.25%.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' FCF Margin soared by 1247900bps in 2021, and later crashed by -4051700bps in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' FCF Margin (Quarter) stood at 66.54% in 2021, then skyrocketed by 31bps to 45.85% in 2022, then surged by 78bps to 10.26% in 2023, then plummeted by -71bps to 17.49% in 2024, then skyrocketed by 173bps to 12.79% in 2025.
  • Its FCF Margin stands at 12.79% for Q4 2025, versus 25.06% for Q3 2025 and 18.02% for Q2 2025.